Harvest One Phase II Clinical Trials on Satipharm CBD GelPell Published in Peer-Reviewed Medical Journal

New Cannabis Ventures
By NCV NewswireAug 13, 2019, 8:53 am250 pts
VANCOUVER, Aug. 13, 2019 /PRNewswire/ – Harvest One Inc. (“Harvest One” or the “Company”) (TSXV: HVT;OTCQX:HRVOF), through its wholly-owned subsidiary Satipharm Ltd. (“Satipharm”), today announced positive results of a Phase 2 clinical trial of its CBD GelPell® capsules in the management of Treatment Resistant…

Read Article Share
Share Article
- email
- x.com
- facebook
- pocket
- reddit
- tumblr
- linkedin
- pinterest

Trending Today on NewsBudz

Legal cannabis market drove over $6 billion in Canadian household spending in 2024 75

Harvest strains 2025: The genetics shaping the future of cannabis 61

Nebraska Officials Respond to Omaha Tribe’s Cannabis Retaliation Claims 60

Week in Weed – November 8, 2025 57

Beer Industry Trade Group Calls Out Hemp THC Sector’s ‘Bad Actors’ For Allegedly Marketing To Children 40

About NewsBudz

NewsBudz is your go-to app for daily cannabis news, covering everything from medical marijuana breakthroughs to recreational cannabis trends and legalization updates.

Our platform aggregates content from over 30 top-tier cannabis news outlets to deliver a curated stream of the latest headlines, insights, and developments across the marijuana and hemp industries.

Whether you're interested in policy reform, health research, cannabis business, CBD, delta 9 products or lifestyle stories, NewsBudz keeps you informed and connected. Accessible on the web and mobile, NewsBudz makes it easy to explore, read, and share cannabis news anytime, anywhere.